Role of cytokines in GVL (ESb lymphoma) and GVHD after adoptive transfer of allogeneic T lymphocytes in mice

Journal of Interferon and Cytokine Research

Volumn 18, Issue 9, 1998, Pages 667-679

  Gresser, Ion ^a,b   Greco, Giampaolo ^a   Santini, Stefano Maria ^a   Woodrow, David ^c   Mecchia, Monica ^a   Parlato, Stefania ^a   Logozzi, Mariantonia ^a   Venditti, Massimo ^a   Maunoury, Marie Thérèse ^d   Belardelli, Filippo ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b CNRS   (France)

^c IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^d INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE;

ADOPTIVE TRANSFER; ALLOGRAFT; ANIMAL CELL; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CELL KILLING; DRUG EFFECT; GRAFT VERSUS HOST REACTION; LYMPHOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN LYMPHOCYTE; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

ANIMALIA;

EID: 0031716565     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.1998.18.667     Document Type: Article

References (52)

1. LARIZZA, L., SCHIRRMACHER, V., GRAF, L., PFLÜGER, E., PERES-MARTINEZ, M., and STÖHR, M. (1984). Suggestive evidence that the highly metastatic variant ESb of the T cell lymphoma Eb is derived from a spontaneous fusion with a host macrophage. Int. J. Cancer 34, 699-707.
2. + T cells and IFN-α/β. Int. J. Cancer 57, 538-543.
3. + T lymphocytes are required for the synergistic action of interferon α/β and adoptively transferred immune cells in the inhibition of visceral ESb metastases. Cancer Res. 55, 6133-6139.
4. SCHIRRMACHER, V., VON HOEGEN, P., GRIESBACH, A., SCHILD, H.-J., and ZANGEMEISTER-WITTKE, U. (1991). Specific eradication of micrometastases by transfer of tumour-immune T cells from major histocompatibility complex congenic mice. Cancer Immunol. Immunother. 32, 373-381.
5. ROCHA, M., UMANSKY, V., LEE, K.H., HACKER, H.J., BENNER, A., and SCHIRRMACHER, V. (1997). Differences between graft-versus-leukemia and graft-versus-host reactivity. I. Interaction of donor immune T cells with tumor and/or host cells. Blood 89, 2189-2202.
6. BORTIN, M.M., RIMM, A.A., SALTZSTEIN, E.C., and RODEY, G.E. (1973). Graft versus leukemia. III. Apparent independent antihost and antileukemic activity of transplanted immunocompetent cells. Transplantation 16, 182-188.
7. BORTIN, M.M., TRUITT, R.L., RIMM, A.A., and BACH, F.H. (1979). Graft-versus-leukemia reactivity induced by alloimmunization without augmentation of graft-versus-host reactivity. Nature 281, 490-491.
8. ANTIN, J.H. (1993). Graft-versus-leukemia: no longer an epiphenomenon. Blood 82, 2273-2277.
9. TRUITT, R.L., LEFEVER, A.V., SHIH, C.C.-Y., JESKE, J.M., and MARTIN, T.M. (1990). Graft-vs.-leukemia effect. In: Graft-vs.-Host Disease. Immunology, Pathophysiology, and Treatment. S.J. Burakoff, H.J. Deeg, J. Ferrara, K. Atkinson (eds.) New York: Marcel Dekker, pp. 177-204.
10. SCHIRRMACHER, V., SHANTZ, G., CLAUER, K., KOMITOWSKI, D., ZIMMERMANN, H.P., and LOHMANN-MATTHES, M.L. (1979). Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. I. Tumor invasiveness in vitro and metastasis formation in vivo. Int. J. Cancer 23, 233-244.
11. GRESSER, I., MAURY, C, WOODROW, D., MOSS, J., GRÜTTER, M.G., VIGNAUX, F., BELARDELLI, F., and MAUNOURY, M.-T. (1988). Interferon treatment markedly inhibits the development of tumor metastases in the liver and spleen and increases survival time of mice after intravenous inoculation of Friend erythroleukemia cells. Int. J. Cancer 41, 135-142.
12. SVETIC, A., FINKELMAN, F.D., JIAN, Y.C., DIEFFENBACH, C.W., SCOTT, D.E., McCARTHY, K.F., STEINBERG, A.D., and GAUSE, W.C. (1991). Cytokine gene expression after in vivo primary immunization with goat antibody to mouse IgD antibody. J. Immunol. 147, 2391-2397.
13. MONTGOMERY, R.A., and DALLMAN, M.J. (1991). Analysis of cytokine gene expression during fetal thymic ontogenic using the polymerase chain reaction. J. Immunol. 147, 554-560.
14. LELLOUCH, J., and LAZAR, P. (1974). Méthodes Statistiques en Expérimentation Biologique. Paris: Flammarion Médecines-Sciences, pp. 147-150.
15. FERRARA, J.L.M., and DEEG, H.J. (1991). Graft-versus-host disease. N. Engl. J. Med. 324, 667-674.
16. JADUS, M.R., and WEPSIC, H.T. (1992). The role of cytokines in graft-versus-host reactions and disease. Bone Marrow Transplant. 10, 1-14.
17. ANTIN, J.H., and FERRARA, J.L.M. (1992). Cytokine dysregulation and acute-graft-versus-host disease. Blood 80, 2964-2968.
18. FERRARA, J.L.M. (1993). Cytokine dysregulation as a mechanism of graft versus host disease. Curr. Opin. Immunol. 5, 794-799.
19. PIGUET, P.-F., GRAU, G.E., ALLET, B., and VASSALLI, P. (1987). Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J. Exp. Med. 166, 1280-1289.
20. PIGUET, P.-F. (1990). Tumor necrosis factor and graft-vs.-host disease In: Graft-vs.-Host Disease. Immunology, Pathophysiology and Treatment. S.J. Burakoff, H.J. Deeg, J. Ferrara, and K. Atkinson (eds.) New York: Marcel Dekker, pp. 255-276.
21. CLEVELAND, M.G., ANNABLE, C.R., KLIMPEL, G.R. (1988). In vivo and in vitro production of IFN-β and IFN-γ during graft vs host disease. J. Immunol. 141, 3349-3356.
22. WALL, D.A., and SHEEHAN, K.C.F. (1994). The role of tumor necrosis factor and interferon gamma in graft-versus-host disease and related immunodeficiency. Transplantation 57, 273-279.
23. SYMINGTON, F.W., SYMINGTON, B.E., LIU, P.Y., VIGUET, H., SANTHANAM, U., and SEHGAL, P.B. (1992). The relationship of serum IL-6 levels to acute graft-versus-host disease and hepatorenal disease after human bone marrow transplantation. Transplantation 54, 457-462.
24. MOWAT, A. McL., and FELSTEIN, M.V. (1990). Intestinal graft-vs.-host reaction. In: Graft-vs.-Host Disease. Immunology, Pathophysiology, and Treatment. S.J. Burakoff, H.J. Deeg, J. Ferrara, K. Atkinson (eds.) New York: Marcel Dekker, pp. 205-243.
25. SNOVER, D.C., WEISDORF, S.A., VERCELLOTTI, G.M., RANK, B., HUTTON, S., and McGLAVE, P.A. (1985). Histopathologic study of gastric and small intestinal graft-versus-host disease following allogeneic bone marrow transplantation. Hum. Pathol. 16, 387-392.
26. MOWAT, A.M., and FELSTEIN, M.V. (1990). Experimental studies of immunologically mediated enteropathy. V. Destructive enteropathy during an acute graft-versus-host reaction in adult BDF1 mice. Clin. Exp. Immunol. 79, 279-284.
27. BESCHORNER, W.E., TUTSCHKA, P.J., and SANTOS, G.W. (1982). Sequential morphology of graft-versus-host disease in the rat radiation chimera. Clin. Immunol. Immunopathol. 22, 203-224.
28. SYKES, M., ROMICK, M.L., HOYLES, K.A., and SACHS, D.H. (1990). In vivo administration of interleukin 2 plus T cell-depleted syngeneic marrow prevents graft-versus-host disease mortality and permits alloengraftment. J. Exp. Med. 171, 645-658.
29. SYKES, M., ROMICK, M.L., and SACHS, D.H. (1990). Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells. Proc. Natl. Acad. Sci. USA 87, 5633-5637.
30. + cells while preserving CD4- and CD8-mediated graft-versus-leukemia effects. Blood 83, 2560-2569.
31. FEFER, A. (1970). Immunotherapy of primary Moloney sarcoma-virus-induced tumors. Int. J. Cancer 5, 327-337.
32. FEFER, A. (1973). Adoptive tumor immunotherapy in mice as an adjunct to whole-body X-irradiation and chemotherapy. Israel J. Med. Sci. 9, 350-365.
33. FEFER, A., EINSTEIN, A.B., and CHEEVER, M.A. (1976). Adoptive chemoimmunotherapy of cancer in animals: a review of results, principles, and problems. Ann. NY Acad. Sci. 277, 492-504.
34. BORTIN, M.M., TRUITT, R.L., and RIMM, A.A. (1978). Non-specific adoptive immunotherapy of T cell acute lymphoblastic leukemia in AKR Mice. A model for the treatment of T cell leukemia in man. In: The Handbook of Cancer Immunotherapy. W.H. Garland (ed.) New York: Garland STPM Press, pp. 403-429.
35. COBBOLD, S.P.O., MARTIN, G., and WALDMANN, H. (1986). Monoclonal antibodies for prevention of graft-versus-host disease and marrow graft rejection: the depletion of T-cell subsets in vitro and in vivo. Transplantation 42, 239-247.
36. KORNGOLD, R., and SPRENT, J. (1985). Surface markers of T cells causing lethal graft-vs.-host disease to class I vs class II H-2 differences. J. Immunol. 135, 3004-3010.
37. WALDMANN, H., COBBOLD, S., and HALE, G. (1994). What can be done to prevent graft versus host disease? Curr. Opin. Immunol. 6, 777-783.
38. PIGUET, P.-F., GRAU, G.E., COLLART, M.A., VASSALLI, P., and KAPANCI, Y. (1989). Pneumopathies of the graft-versus-host reaction. Alveolitis associated with an increased level of tumor necrosis factor mRNA and chronic interstitial pneumonitis. Lab. Invest 61, 37-45.
39. IMAMURA, M., TANAKA, J., HASHINO, S., KOBAYASHI, H., HIRANO, S., MINAGAWA, T., IMAI, K., KOBAYASHI, S., FUJII, Y., KASAI, M., SAKURADA, K., and MIYAZAKI, T. (1994). Cytokines involved in graft-versus-host disease. Hokkaido J. Med. Sci. 69, 1348-1353.
40. HUCHET, R., BRULEY-ROSSET, M., MATHIOT, C., GRANDJON, D., and HALLE-PANNENKO, O. (1993). Involvement of IFN-γ and transforming growth factor-β in graft-vs-host reaction-associated immuno-suppression. J. Immunol. 50, 2517-2524.
41. FERRARA, J.L.M. (1994). Cytokines other than growth factors in bone marrow transplantation. Curr. Opin Oncol. 6, 127-134.
42. SHALABY, M.R., FENDLY, B., SHEEHAN, K., SCHREIBER, R.D., and AMMANN, A.J. (1989). Prevention of the graft versus host reaction in newborn mice by antibodies to tumor necrosis factor-alpha. Transplantation 47, 1057-1061.
43. HERVÉ, P., FLESCH, H.M., TIBERGHIEN, P., WIJDENES, J., RACADOT, E., BORDIGONI, P., PLOUVIER, E., STEPHAN, J.L., BOURDEAU, H., HOLLER, E., LIOURE, B., ROCHE, C., VILMER, E., DEMEOCQ, F., KUENTZ, M., and CAHN, J.Y. (1992). Phase I-II trial of a monoclonal anti-tumor necrosis factor α antibody for the treatment of refractory severe acute graft-versus-host disease. Blood 79, 3362-3368.
44. MOWAT, A. McI. (1989). Antibodies to IFN-γ prevent immunologically mediated intestinal damage in murine graft-versus-host reaction. Curr. Opin. Immunol 68, 18-23.
45. USHIYAMA, C., HIRANO, T., MIYAJIMA, H., OKUMURA, K., OVARY, Z., and HASHIMOTO, H. (1995). Anti-IL-4 antibody prevents graft-versus-host disease in mice after bone marrow transplantation. J. Immunol. 154, 2687-2696.
46. McCARTHY, P.L., ABHYANKAR, S., NEBEN, S., NEWMAN, G., SIEFF, C., THOMPSON, R.C., BURAKOFF, S.J., and FERRARA, J.L.M. (1991). Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus host disease. Blood 78, 1915-1918.
47. BRAUN, M.Y., LOWIN, B, FRENCH, L., ACHA-ORBEA, H., and TSCHOPP, J. (1996). Cytotoxic T cells deficient in both functional Fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host. J. Exp. Med. 183, 657-661.
48. VIA, C.S., RUS, V., GATELY, M.K., and FINKELMAN, F.D. (1994). IL-12 stimulates the development of acute graft-versus-host disease in mice that normally would develop chronic, autoimmune graft-versus-host disease. J. Immunol. 153, 4040-40.
49. SYKES, M., SZOT, G.L., NGUYEN, P.L., and PEARSON, D.A. (1995). Interleukin-12 inhibits murine graft-versus-host disease. Blood 86, 2429-2438.
50. + T cell activity. J. Immunol. 159, 197-205.
51. SYKES, M. (1993). Novel approaches to the control of graft versus host disease. Curr. Opin. Immunol. 5, 774-781.
52. SLAVIN, R.E., and WOODRUFF, J.M. (1974). The pathology of bone marrow transplantation. In: Pathology Annual 1974. S.C. Sommers (ed.) New York: Appleton-Century-Crofts, pp. 291-343.